Kurt Elam joined ACC/Lab Owl in 2017 with 20+ years of specialty biopharmaceutical experience, focused primarily on oncology, infectious disease, and critical care/ICU medicine. He has overseen and managed the successful launch of over 16 new FDA approved products/compounds or new indications, and worked to gain formulary approval in managed care organizations, thereby improving access for patients.
At Maryland Lifesciences’ 2020 Bio Innovation Conference, American Gene Technologies (AGT) took center stage. AGT was the virtual event’s diamond sponsor, AGT’s CEO and Founder Jeff Galvin kicked off the event with opening remarks and then hosted several panel discussions, including “Expanding Progress and Opportunities in Gene and Cell Therapy,” which was a highlight of the conference’s second day.
Maryland is the epicenter of biotech and life science innovation in the BioHealth Capital Region (BHCR). The state is home to a burgeoning life science ecosystem, including a rapidly growing cell and gene therapy industry, a robust and growing advanced biomanufacturing environment, and a deep network of leading research universities and critical government life science research entities.
Jeff Galvin is the CEO and Founder of American Gene Technologies™ (AGT). He earned his BA degree in Economics from Harvard in 1981 and has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups.
Well to say that the first two quarters of 2020 have been eventful in the life science sector is the understatement of the century. The BioBuzz team has been there for every twist and turn as the coronavirus pandemic reshaped everyday life and galvanized the BioHealth Capital Region (BHCR) to rise up and fight COVID-19.
How to Accelerate the Global Cell and Gene Therapy Boom Through Standards and Safety PDA’s Josh Eaton, Assistant Director of Scientific Affairs, shares his thoughts on the Current State of [….]
Impact of the Cell and Gene Therapy Revolution Discussed by CEO of American Gene Technologies Jeff Galvin at Recent PDA Event
Jeff Galvin, CEO of American Gene Technologies shares his vision for the future of the cell and gene therapy revolution.
This Startup is on a Mission to Decentralize Cell and Gene Therapy Clinical Trials For the cell and gene therapy revolution to be fully realized, physicians, research scientists, biomanufacturing experts, [….]